BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,428,898 | +55.2% | 31,363 | +38.2% | 0.05% | +57.6% |
| Q1 2023 | $920,712 | +12.9% | 22,700 | +41.9% | 0.03% | -10.8% |
| Q4 2022 | $815,520 | +292.1% | 16,000 | +314.6% | 0.04% | +311.1% |
| Q3 2022 | $208,000 | -95.4% | 3,859 | -94.5% | 0.01% | -94.3% |
| Q2 2022 | $4,486,000 | -7.4% | 69,829 | +11.7% | 0.16% | +11.3% |
| Q1 2022 | $4,845,000 | +278.8% | 62,487 | +319.4% | 0.14% | +647.4% |
| Q4 2021 | $1,279,000 | -53.6% | 14,900 | -56.5% | 0.02% | -62.0% |
| Q2 2021 | $2,758,000 | -49.6% | 34,268 | -49.7% | 0.05% | -65.3% |
| Q4 2020 | $5,467,000 | +23.0% | 68,129 | +23.3% | 0.14% | +28.6% |
| Q3 2020 | $4,444,000 | +161.6% | 55,264 | +180.1% | 0.11% | +286.2% |
| Q2 2020 | $1,699,000 | +18.4% | 19,732 | +11.6% | 0.03% | -64.2% |
| Q1 2020 | $1,435,000 | -65.4% | 17,676 | -64.4% | 0.08% | +28.6% |
| Q4 2019 | $4,151,000 | +742.0% | 49,651 | +781.9% | 0.06% | +530.0% |
| Q3 2019 | $493,000 | -89.5% | 5,630 | -90.2% | 0.01% | -87.5% |
| Q2 2019 | $4,708,000 | -41.1% | 57,477 | -41.5% | 0.08% | -58.8% |
| Q1 2019 | $7,989,000 | +2065.0% | 98,259 | +1654.6% | 0.19% | +1663.6% |
| Q4 2018 | $369,000 | -68.8% | 5,600 | -63.5% | 0.01% | -50.0% |
| Q3 2018 | $1,184,000 | -33.9% | 15,347 | -36.7% | 0.02% | -33.3% |
| Q2 2018 | $1,791,000 | -67.4% | 24,248 | -71.3% | 0.03% | -61.6% |
| Q1 2018 | $5,492,000 | +646.2% | 84,416 | +640.8% | 0.09% | +760.0% |
| Q4 2017 | $736,000 | +113.3% | 11,396 | +107.5% | 0.01% | +100.0% |
| Q3 2017 | $345,000 | -88.6% | 5,491 | -90.6% | 0.01% | -86.1% |
| Q1 2017 | $3,019,000 | +8.9% | 58,209 | -6.8% | 0.04% | +33.3% |
| Q4 2016 | $2,771,000 | +60.2% | 62,475 | +72.0% | 0.03% | +22.7% |
| Q3 2016 | $1,730,000 | -59.9% | 36,321 | -61.9% | 0.02% | -53.2% |
| Q2 2016 | $4,309,000 | +930.9% | 95,300 | +834.6% | 0.05% | +571.4% |
| Q1 2016 | $418,000 | -58.9% | 10,197 | -61.8% | 0.01% | -74.1% |
| Q4 2015 | $1,017,000 | -87.0% | 26,680 | -88.8% | 0.03% | -85.1% |
| Q3 2015 | $7,830,000 | +782.8% | 238,333 | +1828.3% | 0.18% | +341.5% |
| Q3 2014 | $887,000 | +275.8% | 12,360 | +278.0% | 0.04% | +310.0% |
| Q2 2014 | $236,000 | -49.9% | 3,270 | -48.9% | 0.01% | -66.7% |
| Q1 2014 | $471,000 | +42.7% | 6,400 | +34.7% | 0.03% | +87.5% |
| Q4 2013 | $330,000 | -77.6% | 4,752 | -77.7% | 0.02% | -80.5% |
| Q2 2013 | $1,475,000 | – | 21,287 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |